THE COST-EFFECTIVENESS OF TEMOZOLOMIDE IN THE ADJUVANT TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA IN THE UNITED STATES

被引：0
|
作者：
Messali, A. [1 ]
Hay, J. [1 ]
Villacorta, R. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1195
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A221 / A222
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of concomitant and adjuvant temozolomide for glioblastoma patients with unmethylated O6-methylguanine-DNA methyltransferase promoter regions in the United States.
    Midha, Manav Dev
    Votruba, Mark Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
    Grossman, Stuart A.
    Ye, Xiaobu
    Piantadosi, Steven
    Desideri, Serena
    Nabors, Louis B.
    Rosenfeld, Myrna
    Fisher, Joy
    CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2443 - 2449
  • [23] Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
    Chen, Zhaoyan
    Zhan, Mei
    Tian, Fangyuan
    Xu, Ting
    ONCOLOGY LETTERS, 2020, 19 (01) : 424 - 430
  • [24] The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma
    Sher, David J.
    Henson, John W.
    Avutu, Bindu
    Hochberg, Fred H.
    Batchelor, Tracy T.
    Martuza, Robert L.
    Barker, Fred G., II
    Loeffler, Jay S.
    Chakravarti, Arnab
    JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (01) : 43 - 50
  • [25] The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma
    David J. Sher
    John W. Henson
    Bindu Avutu
    Fred H. Hochberg
    Tracy T. Batchelor
    Robert L. Martuza
    Fred G. Barker
    Jay S. Loeffler
    Arnab Chakravarti
    Journal of Neuro-Oncology, 2008, 88 : 43 - 50
  • [26] The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
    Bernard-Arnoux, F.
    Lamure, M.
    Ducray, F.
    Aulagner, G.
    Honnorat, J.
    Armoiry, X.
    NEURO-ONCOLOGY, 2016, 18 (08) : 1129 - 1136
  • [27] Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma
    Ly, Ina
    Richardson, Leland
    Liu, Mofei
    Muzikansky, Alona
    Lou, Kevin
    Reardon, David A.
    Arrillaga-Romany, Isabel
    Forst, Deborah Anne
    Jordan, Justin T.
    Lee, Eudocia Quant
    Dietrich, Jorg
    Nayak, Lakshmi
    Wen, Patrick Y.
    Chukwueke, Ugonma Nnenna
    Giobbie-Hurder, Anita
    Choi, Bryan D.
    Batchelor, Tracy
    Kalpathy-Cramer, Jayashree
    Curry, William T.
    Gerstner, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
    Ahluwalia, Manmeet S.
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Figel, Sheila A.
    Mechtler, Laszlo L.
    Peereboom, David M.
    Hutson, Alan D.
    Withers, Henry G.
    Liu, Song
    Belal, Ahmed N.
    Qiu, Jingxin
    Mogensen, Kathleen M.
    Dharma, Sanam S.
    Dhawan, Andrew
    Birkemeier, Meaghan T.
    Casucci, Danielle M.
    Ciesielski, Michael J.
    Fenstermaker, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1453 - +
  • [29] The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation
    Anderson, Rob
    Dyer, Matthew
    Garside, Ruth
    Mealing, Stuart
    Pitt, Martin
    Price, Alison
    Rogers, Gabriel
    Somerville, Margaret
    Stein, Ken
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (45) : 1 - +
  • [30] A cost-effectiveness model of topiramate treatment for newly diagnosed epilepsy in the UK
    Remak, E.
    Hutton, J.
    Price, M.
    Peeters, K.
    Adriaenssen, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 85 - 85
12345